Label antibodies, small molecules, proteins, or peptides with VivoTag® NIR fluorescent dyes.
Available as either NHS esters or maleimide reactive dyes, making conjugation to either free amine (-NH3) or free thiol (-SH) containing molecules possible, our VivoTag fluorescent dyes have been validated for in vivo and in vitro applications. Please refer to the configuration table below to see which VivoTag fluorescent agent is best for your research studies.
VivoTag is available in multiple sizes and wavelengths to fit your imaging needs.
true falseFor laboratory use only. This product is intended for animal research only and not for use in humans.
Vivotag-S® Fluorochrome in 1 mg quantity size. VivoTag-S fluorochrome is an amine-reactive near-infra-red fluorochrome for coupling via an NHS ester linkage to peptides, small molecules, proteins, antibodies or macromolecules.
| Product | Abs/Em (nm) | |
| VIVOTAG | ||
| VivoTag 645 | 643/660 | Suitable for labeling free amines (typically lysine residues) |
| VivoTag 680 XL | 665/688 | |
| VivoTag 800 | 785/810 | |
| VIVOTAG MAL | ||
| VivoTag 645 MAL | 643/660 | Suitable for labeling free thiols (typically cycteine residues) |
| VivoTag 680 XL MAL | 665/688 | |
| VIVOTAG-S | ||
| VivoTag 680-S | 665/688 | "S" for self-quenching. When a protein is labeled with multple VivoTag-S molecules, there is a shift in the absorbance of the dye, which will reduce the signal. Only choose 'S' form if your labeling ratio of dye:protien will be 1:1. If multiple dyes are to be conjucated onto your protein, the non-"S" version should be used. Suitable for labeling free amines (typically lysine residues) |
| VivoTag 750-S | 750/775 | |
| Optical Imaging Classification | Fluorescence Imaging |
|---|---|
| Product Brand Name | VivoTag |
| Shipping Condition | Blue Ice |
| Unit Size | 1 mg |
| Wave Length | 680 nm |
N-Hydroxysuccinimide (NHS)-ester labeling reagents, such as VivoTag®-S reagents, are commonly used for labeling proteins. The NHS ester moiety reacts with amino groups at pH 7-9 to form stable amide bonds. Lysines within proteins, including antibodies, are available as targets for this chemical conjugation.,Protein labeling efficiency may vary depending upon the type of protein labeled, so different conjugation ratios may need to be attempted to attain success. For Near Infrared (NIR) fluorophore conjugation, ratios of fluorophore to protein of 4:1 have been seen to generate effective imaging agents. Not all antibodies or proteins (independent of target specificity) make good imaging agents, due to long half-lives and/or excessive accumulation in non-target sites.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
We have developed a novel FAST (“Fluorescent Activatable Sensor Technology”) in vivo imaging agent based on an angiotensinogen substrate sequences that is selectively cleaved and activated by rodent renin. ReninSense680 FAST, a PKM-modified agent suitable for invivo administration, distributes to the kidney, is activated in a model of renin upregulation, and provides a tool for in vivo imaging and quantification of the changes in renin activity inkidneys and plasma.
VivoTag-S® 680 is an amine reactive near-infrared (NIR) fluorochrome (NHS ester) for labeling biomolecules for in vivo imaging applications.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.
